TY - JOUR
T1 - SAFER-ROP
T2 - Updated protocol for anti-VEGF injections for retinopathy of prematurity
AU - Beck, Kinley D.
AU - Rahman, Effie Z.
AU - Ells, Anna
AU - Mireskandari, Kamiar
AU - Berrocal, Audina M.
AU - Armitage Harper, C.
N1 - Publisher Copyright:
© 2020 Beck, Rahman, Ells, et al.; licensee SLACK Incorporated.
PY - 2020/7
Y1 - 2020/7
N2 - BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.
AB - BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.
UR - http://www.scopus.com/inward/record.url?scp=85088682251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088682251&partnerID=8YFLogxK
U2 - 10.3928/23258160-20200702-05
DO - 10.3928/23258160-20200702-05
M3 - Article
C2 - 32706898
AN - SCOPUS:85088682251
VL - 51
SP - 402
EP - 406
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
SN - 2325-8160
IS - 7
ER -